Spherix Global Insights Partners with the American Kidney Fund
EXTON, PA – Spherix Global Insights announces an exciting partnership with the American Kidney Fund (AKF), creating a landmark collaboration to improve kidney care for patients. This strategic alliance merges Spherix's exceptional market intelligence capabilities with AKF's esteemed patient advocacy efforts, focusing on addressing the numerous unmet needs within the renal community.
Inaugural Initiative: Patient Dynamix™ on IgA Nephropathy
The first research project launched under this partnership, called Patient Dynamix™: IgA Nephropathy (US), aims to gather insights directly from patients affected by this rare but serious condition. IgA Nephropathy (IgAN) is increasingly recognized as one of the leading causes of kidney disease, and many patients may progress to end-stage renal disease (ESRD). Understanding the patient experience is crucial for shaping effective care strategies and promoting timely interventions to mitigate disease progression.
Patient Engagement in Healthcare
Meghan Weiss, head of the Spherix Nephrology Franchise, emphasized the importance of understanding the challenges faced by these patients: "Now, more than ever, it is vital for healthcare companies to engage with patient communities to fully grasp the breadth of challenges they face. Through this research, we aim to bridge gaps in understanding and amplify the patient voice in IgAN treatment and care." This highlights the pressing need for healthcare solutions that truly resonate with patient experiences and preferences.
Understanding the Growing Concern of IgAN
LaVarne A. Burton, President and CEO of AKF, stated, "In recent years we have seen an increasing prevalence of IgAN – a concerning trend for this serious and life-altering condition. With new therapies emerging and further research anticipated, our collaboration with Spherix represents a significant step toward addressing the unmet needs in treating and managing IgAN." This partnership aims to address both immediate and long-term challenges faced by individuals dealing with this condition.
Exploring Patient Experiences
Through this research initiative, Spherix and AKF will delve into various facets of the IgAN patient journey, producing valuable insights such as:
- Patient demographics, health perceptions, and disease progression
- Experiences surrounding diagnosis and evaluations of quality of life
- Preferences and behaviors concerning treatment information-seeking
- Interactions and challenges with insurance providers
- Support desires from healthcare teams and pharmaceutical entities
- Current treatment experiences with therapies like budesonide, sparsentan, and iptacopan
- Patient preferences regarding new treatment formats and methods of administration
Leveraging Expertise for Better Outcomes
This partnership intends to make the most of AKF's position as a leading patient advocacy organization, combined with Spherix’s expertise in rare renal diseases. The goal is to convert this collaborative effort into actionable data that can empower stakeholders, enhancing patient experiences and raising standards of care within the kidney health sector.
About Spherix Global Insights
Spherix is recognized as an independent leader in market intelligence and advisory services, delivering substantial commercial value across the global life sciences landscape. With a dedicated team of experts, Spherix offers a comprehensive view of rapidly evolving specialty markets such as nephrology, among others. Their reliable insights and advisory services enable clients to make well-informed decisions, fostering growth opportunities.
About the American Kidney Fund
AKF plays a pivotal role in addressing kidney disease nationwide. As a nonprofit organization with a profound impact on the lives of individuals living with kidney disease, AKF supports prevention, disease management, financial assistance, clinical research, and policy advocacy. Their unparalleled commitment ensures that significant portions of every donation go directly to programs that benefit patients, maintaining high ratings from entities like Charity Navigator and Candid.
To learn more about the partnership, please reach out to:
Spherix Global Insights Contacts
Meghan Weiss, Nephrology Franchise Head
Meghan.weiss@spherixglobalinsights.com
American Kidney Fund Contacts
Nancy Gregory, Senior Director of Communications
Frequently Asked Questions
What is the purpose of the Spherix and AKF partnership?
The collaboration aims to improve kidney care by integrating market intelligence with patient advocacy, focusing on enhancing the treatment and management of IgAN.
What is IgA Nephropathy?
IgA Nephropathy is a kidney condition characterized by the accumulation of IgA antibodies in the kidney, which can lead to kidney damage and eventually renal failure.
How will this research benefit kidney patients?
The research will provide insights into the patient experience, informing better treatment options and support structures for those living with IgAN.
Who is leading the initiative at Spherix?
Meghan Weiss oversees the nephrology franchise at Spherix Global Insights, playing a crucial role in the initiative.
How does AKF support kidney patients?
AKF offers various programs for kidney disease prevention, management, financial aid, and advocacy, helping individuals navigate their health journeys.
